-
ASCO 2024丨Professor Zengjun Li: SHR-A1912 Phase I Study Results First Unveiled, Pioneering a New Chapter in B-NHL Treatment
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was grandly held in Chicago from May 31 to June 4. At this conference, Chinese researchers presented the first results of the Phase I study of SHR-A1912 in patients with B-cell non-Hodgkin lymphoma (B-NHL) on the international stage, including preliminary key data from the dose-escalation…
-
Professor Ying Wang: The Advantages and Prospects of CN201 in Treating Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia (R/R B-ALL)
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting took place in Chicago, USA, from May 31 to June 4. The ASCO Annual Meeting gathers oncology experts, doctors, and researchers from around the world to share the latest research findings, discuss cutting-edge diagnostic and therapeutic techniques, and advance the field of oncology. A study…
-
ASCO & EHA Special丨Professor Jun Zhu: Opportunities and Challenges for Chinese Original Anticancer Drugs on the International Stage
As summer begins, the sun shines warmly and everything thrives. In this vibrant season, two major international events in the pharmaceutical world—the American Society of Clinical Oncology (ASCO 2024) and the European Hematology Association (EHA 2024) annual meetings—are about to take place. These meetings are not only platforms for showcasing global pharmaceutical innovations but also…
-
Professor Man Li: From Uncertainty to Definitive Evidence—PostMONARCH Study Proves the Benefit of Cross-Line Treatment with CDK4/6 Inhibitors| Man Talks Breast Cancer: ASCO Special
In this “Man Talks Breast Cancer: ASCO Special,” Professor Man Li’s team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in…
-
EASL Special New Voices丨Latest Advances in ACLF: Transition from ACLF to Pre-ACLF
From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. This event brought together over 7,000 liver disease specialists from around the world. On the third day of the conference, “Hepatology Digest” invited Dr. Wenyi Gu, a protégé of Professors Jonel Trebicka from University…
-
EASL China Voice: Professor Liang Peng’s Team Reveals Key Mechanism of Pyroptosis in Hepatocytes Mediating ACLF Liver Injury
From June 5 to 8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy. During the conference, Professor Liang Peng’s team from the Third Affiliated Hospital ,Sun Yat-sen University unveiled the significant link between hepatocyte pyroptosis and acute-on-chronic liver failure (ACLF). The research found that…
-
EASL2024 Interview | Dr. Terry Yip: Prognostic significance of a change in liver stiffness measurement in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
With the rapid development of modern medical technology, non-invasive assessment methods have attracted more and more attention. In the field of metabolically associated fatty liver disease (MAFLD), liver hardness measurement (LSM) has become an important indicator for non-invasive assessment of liver-related events. At the annual meeting of the European Association for the Study of the…
-
Professor Yongxian Hu: Advances in CD7 CAR-T Cell Therapy丨2024 Nanjing Lymphoma Forum
With the continuous advancement of immunotherapy technologies, CD7 CAR-T cell therapy is emerging as a new option for treating leukemia and lymphoma, showing significant potential. Recent clinical studies have revealed multiple new developments in CD7 CAR-T cell therapy. However, challenges remain, such as improving safety, reducing side effects, and optimizing treatment protocols to enhance long-term…
Connecting Medical Expertise through Media